DMAC

DiaMedica Therapeutics Inc. [DMAC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

DMAC Stock Summary

Top 10 Correlated ETFs

DMAC


Top 10 Correlated Stocks

DMAC


In the News

06:00 29 Mar 2024 DMAC

Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich

The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of the analysts' favorite penny stocks.

09:53 29 Mar 2024 DMAC

DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023

DiaMedica Therapeutics (NASDAQ: DMAC ) just reported results for the fourth quarter of 2023. DiaMedica Therapeutics reported earnings per share of -14 cents.

12:10 29 Mar 2024 DMAC

DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alexander Nowak - Craig-Hallum Capital Group Francois Brisebois - Oppenheimer. Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Third Quarter 2023 Conference Call.

11:17 29 Mar 2024 DMAC

Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?

Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year.

03:43 29 Mar 2024 DMAC

DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2023 Earnings Call Transcript August 15, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak - Craig-Hallum Capital Group Dan Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.

08:32 29 Mar 2024 DMAC

DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Monday, August 14th. DiaMedica will host a live conference call on Tuesday, August 15th at 7:00 AM Central Time to provide a business update and discuss financial results. Co.

09:11 29 Mar 2024 DMAC

DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2023 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak - Craig-Hallum Daniel Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.

08:50 29 Mar 2024 DMAC

DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2023 financial results will be released after the markets close on Monday, May 15th. DiaMedica will host a live conference call on Tuesday, May 16th at 7:00 AM Central Time to provide a business update and discuss financial results. Conferenc.

10:01 29 Mar 2024 DMAC

DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2022 Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Kirsten Gruis - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Capital Group Daniel Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics ReMEDy2 Update Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.

04:17 29 Mar 2024 DMAC

DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on Tuesday, March 28th. DiaMedica will host a live conference call on Wednesday, March 29th at 7:00 AM Central Time to provide a business update and discuss financial results.

DMAC Financial details

Company Rating
Buy
Market Cap
104.38M
Income
-19.38M
Revenue
0
Book val./share
1.35
Cash/share
1.39
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-6.21
Forward P/E
-3.23
PEG
-3.23
P/S
-
P/B
2.01
P/C
2
P/FCF
-6.29
Quick Ratio
21.56
Current Ratio
22.07
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.62
EPS next Y
-0.86
EPS next Q
-0.19
EPS this Y
15.38%
EPS next Y
38.71%
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
16.67%
-
-
-
-
SMA20
-
SMA50
-
SMA100
50%
Inst Own
11.85%
Inst Trans
0.9%
ROA
-31%
ROE
-41%
ROC
-0.44%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
37.96M
Shs Float
23.53M
-
-
-
-
Target Price
-
52W Range
1.46-4.75
52W High
-30.5%
52W Low
+178%
RSI
40
Rel Volume
0.46
Avg Volume
39.49K
Volume
18.19K
Perf Week
0.36%
Perf Month
-7.33%
Perf Quarter
23.01%
Perf Half Y
8.59%
-
-
-
-
Beta
1.711
-
-
Volatility
0.05%, 0.14%
Prev Close
4.91%
Price
2.78
Change
1.46%

DMAC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.89-0.78-0.65-0.52-0.6
Operating cash flow per share
-0.76-0.59-0.59-0.44-0.58
Free cash flow per share
-0.76-0.59-0.59-0.44-0.58
Cash per share
0.661.752.171.271.62
Book value per share
0.641.662.121.21.57
Tangible book value per share
0.641.662.121.21.57
Share holders equity per share
0.641.662.121.21.57
Interest debt per share
0.010.01000.01
Market cap
58.14M159M77.48M41.78M92.49M
Enterprise value
54.44M151.71M72.83M37.52M88.35M
P/E ratio
-5.46-12.94-5.7-3.05-4.77
Price to sales ratio
00000
POCF ratio
-6.39-17.31-6.32-3.63-4.94
PFCF ratio
-6.39-17.22-6.31-3.6-4.93
P/B Ratio
7.636.111.761.311.81
PTB ratio
7.636.111.761.311.81
EV to sales
00000
Enterprise value over EBITDA
-5.08-12.16-5.35-2.68-4.16
EV to operating cash flow
-5.98-16.52-5.94-3.26-4.72
EV to free cash flow
-5.98-16.43-5.93-3.24-4.71
Earnings yield
-0.18-0.08-0.18-0.33-0.21
Free cash flow yield
-0.16-0.06-0.16-0.28-0.2
Debt to equity
0.02000.010.01
Debt to assets
0.02000.010.01
Net debt to EBITDA
0.350.580.340.30.2
Current ratio
6.713.7729.8215.6119.27
Interest coverage
00039.660
Income quality
0.850.750.90.840.97
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.0100.010
Capex to revenue
00000
Capex to depreciation
-0.1-2.24-0.92-3.24-0.8
Stock based compensation to revenue
00000
Graham number
3.565.415.593.744.58
ROIC
-1.46-0.48-0.31-0.43-0.41
Return on tangible assets
-1.18-0.44-0.3-0.4-0.36
Graham Net
0.591.642.111.171.54
Working capital
7.52M25.89M43.92M31.67M50.89M
Tangible asset value
7.62M26.01M44.02M31.83M51.06M
Net current asset value
7.4M25.84M43.91M31.27M50.57M
Invested capital
0.02000.010.01
Average receivables
801.5K581.5K235K106K225.5K
Average payables
332.5K640.5K804K621.5K830K
Average inventory
44K49K61.5K56.5K0
Days sales outstanding
00000
Days payables outstanding
3.16K19.1K7.74K10.72K11.27K
Days of inventory on hand
1.53K173.811.72K00
Receivables turnover
00000
Payables turnover
0.120.020.050.030.03
Inventory turnover
0.242.10.2100
ROE
-1.4-0.47-0.31-0.43-0.38
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.14-0.2-0.16-0.12-0.14
Operating cash flow per share
-0.1-0.19-0.18-0.13-0.09
Free cash flow per share
-0.11-0.19-0.18-0.13-0.09
Cash per share
1.271.081.481.221.39
Book value per share
1.21.022.191.471.35
Tangible book value per share
1.21.022.191.471.35
Share holders equity per share
1.21.022.191.471.35
Interest debt per share
0.01-0.20.020.010.01
Market cap
41.78M40.47M117.99M97.91M107.8M
Enterprise value
37.52M38.78M112.59M96.1M103.66M
P/E ratio
-2.78-1.92-6.59-5.47-5.22
Price to sales ratio
00000
POCF ratio
-15.1-7.95-23.46-20.41-30.11
PFCF ratio
-14.93-7.94-23.44-20.37-30.09
P/B Ratio
1.311.51.971.762.11
PTB ratio
1.311.51.971.762.11
EV to sales
00000
Enterprise value over EBITDA
-9.46-7.03-23.78-9.32-17.75
EV to operating cash flow
-13.57-7.62-22.38-20.03-28.96
EV to free cash flow
-13.41-7.61-22.37-19.99-28.93
Earnings yield
-0.09-0.13-0.04-0.05-0.05
Free cash flow yield
-0.07-0.13-0.04-0.05-0.03
Debt to equity
0.010.020.010.010.01
Debt to assets
0.010.020.010.010.01
Net debt to EBITDA
1.070.311.140.180.71
Current ratio
15.6110.5521.1922.0719.27
Interest coverage
17.350.96000
Income quality
0.740.971.121.070.69
Dividend Yield
000.3100
Payout ratio
00-8.2600
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010000
Capex to revenue
00000
Capex to depreciation
-5.33-1-0.57-1.25-0.34
Stock based compensation to revenue
00000
Graham number
1.962.142.841.972.03
ROIC
-0.12-0.2-0.08-0.18-0.11
Return on tangible assets
-0.11-0.17-0.07-0.08-0.1
Graham Net
1.170.961.41.161.32
Working capital
31.67M26.86M39.29M45.72M50.89M
Tangible asset value
31.83M27.02M59.74M55.63M51.06M
Net current asset value
31.27M26.48M38.92M45.38M50.57M
Invested capital
0.010.020.010.010.01
Average receivables
78.5K69.5K122.5K249K339.5K
Average payables
799K1.26M1.32M859.5K894.5K
Average inventory
4.5K-28.5K-122.5K-94K0
Days sales outstanding
00000
Days payables outstanding
11.01K29.0216.2515.0610.42K
Days of inventory on hand
0-0.93-3.5700
Receivables turnover
00000
Payables turnover
0.013.15.545.980.01
Inventory turnover
0-96.86-25.2200
ROE
-0.12-0.2-0.07-0.08-0.1
Capex per share
00000

DMAC Frequently Asked Questions

What is DiaMedica Therapeutics Inc. stock symbol ?

DiaMedica Therapeutics Inc. is a US stock , located in Minneapolis of Mn and trading under the symbol DMAC

What is DiaMedica Therapeutics Inc. stock quote today ?

DiaMedica Therapeutics Inc. stock price is $2.78 today.

Is DiaMedica Therapeutics Inc. stock public?

Yes, DiaMedica Therapeutics Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap